IMMIX BIOPHARMA INC (IMMX) — insider trading
Health Care · NASDAQ
IMMIX BIOPHARMA INC (IMMX) has 22 reported SEC Form 4 insider transactions in our data, including 2 open-market purchases among the most recent 22 (latest 2026-05-22).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-05-22 | BUCHAN JANE | Director | Grant / award / vesting (derivative) | 12,500 | $0.00 | $0 | Form 4 |
| 2026-05-22 | BUCHAN JANE | Director | Grant / award / vesting | 6,250 | $0.00 | $0 | Form 4 |
| 2026-05-22 | Hsu Jason | Director | Grant / award / vesting (derivative) | 12,500 | $0.00 | $0 | Form 4 |
| 2026-05-22 | Hsu Jason | Director | Grant / award / vesting | 6,250 | $0.00 | $0 | Form 4 |
| 2026-05-22 | Chudnovsky Yekaterina | Director | Grant / award / vesting (derivative) | 12,500 | $0.00 | $0 | Form 4 |
| 2026-05-22 | Chudnovsky Yekaterina | Director | Grant / award / vesting | 6,250 | $0.00 | $0 | Form 4 |
| 2026-05-22 | Rachman Ilya M | Director, Officer (CEO and Chairman) | Grant / award / vesting (derivative) | 500,000 | $0.00 | $0 | Form 4 |
| 2026-05-22 | CHANG NANCY T | Director | Grant / award / vesting (derivative) | 12,500 | $0.00 | $0 | Form 4 |
| 2026-05-22 | CHANG NANCY T | Director | Grant / award / vesting | 6,250 | $0.00 | $0 | Form 4 |
| 2026-05-22 | Morris Gabriel S | Director, Officer (CFO, President) | Grant / award / vesting (derivative) | 500,000 | $0.00 | $0 | Form 4 |
| 2026-05-22 | Marquet Magda | Director | Grant / award / vesting (derivative) | 12,500 | $0.00 | $0 | Form 4 |
| 2026-05-22 | Marquet Magda | Director | Grant / award / vesting | 6,250 | $0.00 | $0 | Form 4 |
| 2026-05-22 | Ng Carey | Director | Grant / award / vesting (derivative) | 12,500 | $0.00 | $0 | Form 4 |
| 2026-05-22 | Ng Carey | Director | Grant / award / vesting | 6,250 | $0.00 | $0 | Form 4 |
| 2026-05-22 | Adams Helen C. | Director | Grant / award / vesting (derivative) | 12,500 | $0.00 | $0 | Form 4 |
| 2026-05-22 | Adams Helen C. | Director | Grant / award / vesting | 6,250 | $0.00 | $0 | Form 4 |
| 2025-12-10 | Morris Gabriel S | Director, Officer (CFO) | Open-market purchase | 770 | $6.58 | $5.1K | Form 4 |
| 2025-12-10 | Rachman Ilya M | Director, Officer (CEO and Chairman) | Open-market purchase | 746 | $6.67 | $5.0K | Form 4 |
| 2025-12-08 | Morris Gabriel S | Director, Officer (CFO) | Option exercise (in/at-the-money) (derivative) | 60,000 | $0.00 | $0 | Form 4 |
| 2025-12-08 | Morris Gabriel S | Director, Officer (CFO) | Option exercise (in/at-the-money) (derivative) | 96,000 | $0.00 | $0 | Form 4 |
| 2025-12-08 | Morris Gabriel S | Director, Officer (CFO) | Option exercise (in/at-the-money) | 156,000 | $0.80 | $124.8K | Form 4 |
| 2025-11-21 | CHANG NANCY T | Director | Grant / award / vesting (derivative) | 39,643 | $0.00 | $0 | Form 4 |
Ask the chat about IMMX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: IMMIX BIOPHARMA INC (IMMX).
Last updated 2026-05-22 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.